MedTrace Logo

AMISH : Aprovel for Management of Isolated Systolic Hypertension

NCT00264212 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 436

Last updated 2007-12-21

No results posted yet for this study

Summary

To compare the antihypertensive efficacy and tolerability of irbesartan and irbesartan-hydrochlorothiazide fixed combination therapy with amlodipine and amlodipine plus hydrochlorothiazide in the treatment of isolated systolic hypertension.

Conditions

Interventions

DRUG

irbesartan and irbesartan-hydrochlorothiazide

Sponsors & Collaborators

Principal Investigators

  • Pascale BLONDIN, MD · Sanofi

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-08-31

Countries

  • Chile
  • China
  • Indonesia
  • Mexico
  • Philippines
  • South Korea
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00264212 on ClinicalTrials.gov